

# Spectroscopic Investigation on the Interaction between 4-Amino Salicylic Acid (PAS) with Bovine Serum Albumin (BSA)

Mamali Priyadarshinee, Bairagi C. Mallick\*

Department of Chemistry, Ravenshaw University, Cuttack-753003, Odisha, India

**Abstract:** PAS (4-amino salicylic acid) is a potential antimicrobial drug used for the treatment of *Mycobacterium tuberculosis* drug resistance. Its interaction with bovine serum albumin (BSA) is important to understand the mechanism of drug-protein interactions and its effectiveness to treat the drug resistance. The binding of PAS with BSA, investigated by UV-visible and fluorescence measurements clearly indicates the conformational stability of the protein. Further, FT-IR and CD spectroscopic methods support the results with increasing secondary structure content of the protein in the presence of drug.

**Keywords:** Bovine serum albumin (BSA), 4-aminosalicylic acid (PAS), fluorescence, FT-IR and CD spectroscopy.

## 1. Introduction

*Mycobacterium tuberculosis*, the human pathogen causing tuberculosis claims nearly about 2 million lives each year, and it is estimated that one third of the total global population is latently affected by this bacilli.[1] The alarming rise of multi drug resistant in the treatment of *M. tuberculosis* can be overcome through the production of new anti-tuberculosis agents, which can be better understood by determining the pharmacodynamic and pharmacokinetic properties. Unlike many drugs, para amino salicylic acid (PAS) is an antimicrobial drug used for multidrug resistant tuberculosis treatment. PAS has been clinically used as a prodrug to combat the pathogenesis of *M. tuberculosis* through the depletion of tetrahydrofolate (THF), which is essential for protein synthesis, resulting in inhibition of bacterial growth and death.[2-4] It also acts as NF- $\kappa$ B (nuclear factor-kappa B) inhibitor and free radical scavenger.

Bovine serum albumin is one of the most important proteins in the circulatory system, accounts for about 60% of the total plasma protein. Albumin constitutes the main protein fraction (~5%) in blood plasma (as albumin contains both basic and acidic groups, it can bind basic and acidic drugs. Serum albumin acts as a major depot and transport protein, capable of binding and delivering drug or other endogenous and exogenous compounds to the target organs. [5,6] Among the serum albumins, Bovine Serum Albumin (BSA), with a molecular weight  $68,000 \text{ g mol}^{-1}$  has wide range of physiological functions.[7-10] BSA contains 583 amino acids in a single polypeptide chain, 17 disulfide bridges and one free -SH group, which can cause it to form a covalently linked dimer. BSA contains two tryptophan (Trp) residues, one located on the surface of the molecule (Trp-134) and the other at the bottom of hydrophobic cleft between domains I and III (Trp-212). It also has a high degree of  $\alpha$ -helical content lying on the surface of hypothetical cylinder with an open channel running along the axis. BSA is known to exhibit a very high conformational adaptability to large variety of ligands. [11,12] Thus, the present study was aimed to investigate the *in-vitro* interaction of PAS with BSA, and

its conformational stability through UV-visible, fluorescence, FT-IR and CD spectroscopic methods. The results obtained will be correlated to the *in-vivo* mechanisms of drug-protein interactions and the possible improved pathways of treatments.

## 2. Materials and Methods

Fatty acid free Bovine Serum Albumin (BSA, purity is > 96% as stated by manufacturer) and 4-amino salicylic acid (PAS) were purchased from Sigma Aldrich Company, USA. The buffer (Tris-HCl) was obtained from MP-Biochem Ltd. (India). The protein was used without further purification.

### 2.1. UV-visible Measurements

The stock solutions of BSA ( $5 \times 10^{-3} \text{ M}$ ) and drug 4-Amino Salicylic Acid ( $5 \times 10^{-3} \text{ M}$ ) based on their molecular weight 66.5 KD and  $135.14 \text{ g mole}^{-1}$  respectively were prepared in 50 mM Tris-HCl, 0.5 M NaCl buffer solution at pH of 7.2. All solutions were prepared in deionised milli-Q water and degassed before used for the experiment. Each time the sample solutions were prepared freshly for each measurement. The absorption spectra were recorded using a Carry-100 UV-visible spectrophotometer with quartz cuvette of path length 1-cm. The absorption was monitored by keeping the protein concentration ( $10 \mu\text{M}$ ) constant and varying the concentration of drug from 0 to  $50 \mu\text{M}$ . Baseline was corrected using 50 mM Tris-HCl, 0.5 M NaCl buffer solution at pH of 7.2.

### 2.2. Intrinsic Fluorescence Measurements

The fluorescence measurements were recorded with a Cary Eclipse Spectrofluorimeter (Agilent) at different concentration of drug ( $10\text{-}50 \mu\text{M}$ ) keeping the concentration of protein ( $10 \mu\text{M}$ ) constant. The emission intensity of tryptophan residues of proteins at 340 nm (excitation wavelength 295nm) was monitored using drug as quencher with increasing concentrations.

### 2.3. Circular Dichroism

CD spectra was recorded on a JASCO-J815 spectropolarimeter (JASCO, Japan) using a 0.1 cm quartz cell. CD spectra of BSA in the presence and absence of PAS were recorded from 190 nm to 260 nm. The overall concentration of BSA was kept at 10  $\mu$ M while the molar ratios of BSA to PAS ranged from 1:1 to 1:5. The raw data were used to calculate mean residue ellipticities  $[\theta]_{222}$  using equation:

$$[\theta]_{222} = 100 \times \theta \times Mw / (c \times l) \quad (1)$$

Here,  $c$  is the protein concentration in molar, and  $l$  the cell pathlength in cm,  $Mw$  is the molecular weight of BSA and  $n$  is the number of amino acid residues in BSA. The factor of 100 converts pathlength in meters.

### 2.4. Fourier Transformed Infrared Spectroscopy


The FT-IR spectra of BSA solution ( $5 \times 10^{-3}$  M) was recorded on a Burkert vector 22 Spectrophotometer (Burkert, Ettlingen, Germany) equipped with a Germanium attenuated total

reflection accessory and a KBR beam splitter. FT-IR spectra of free BSA solution were acquired by subtracting the absorption of the buffer solution from the protein solution and a difference spectrum was obtained by subtracting the spectrum of PAS solution from that of BSA-PAS solution.

## 3. Results and Discussion

### 3.1. UV absorption spectra of BSA in the presence of PAS

The absorption maximum of BSA at 278 nm is characteristic absorption of nonpolar residues like tryptophan (Trp) and tyrosine (Tyr) in BSA. The absorption spectra of BSA alone and its complexation to PAS upon interaction is shown in the Fig.1. It is evident that the drug has no absorbance at 276 nm, which is typical for tryptophan residue. The absorbance upon complexation with BSA, there is increases in absorbance at 276 nm. Thus, the complexation due to drug binding results in conformational changes in BSA at physiological pH 7.2.



**Figure 1:** UV-vis absorption spectra of BSA (a), BSA-PAS (b) and PAS (c) at 298 K.  $c(\text{BSA}) = 10 \mu\text{M}$  and  $c(\text{PAS}) = 50 \mu\text{M}$  respectively.


### 3.2. Fluorescence emission spectra of BSA in the presence of PAS

Generally, the fluorescence of protein is due to the intrinsic fluorescence of three molecules present in the protein, i.e., Trp, Tyr, Phe residues. Actually, the intrinsic fluorescence of many proteins is mainly contributed by tryptophan alone because of very low quantum yield of Phe, and the fluorescence of Tyr is almost quenched via energy transfer to Trp, if Tyr is ionised near an amino or carboxyl group. In order to confirm the interaction between BSA and PAS is carried by keeping the concentration of protein constant while varying the concentration of the drug. Before to record the fluorescence intensity of BSA in the presence of drug, the fluorescence intensity of 4-aminosalicylic acid is measured at excitation wavelength 295nm. The drug used in this study is emissive. It has an emission wavelength at 390nm. The emission intensity of BSA is found to be

quenched gradually on increasing the concentration of drug because of the changes in secondary and tertiary structure of protein in buffer medium affecting the orientation of tryptophan residues of protein. The extent of quenching gives an idea about the interaction of protein with the drug. The Stern- Volmer quenching constant ( $K_{SV}$ ) values are obtained quantitatively by the plot  $F_0/F - 1$  vs  $[Q]$  using the Stern-Volmer modified equation:

$$F_0 / F = 1 + K_{SV}[Q] \quad (2)$$

Here,  $F_0$  and  $F$  are the fluorescence intensities of proteins in the absence and presence of drugs. The obtained  $K_{SV}$  value of  $1.4 \times 10^3 \text{ M}^{-1}$  provides a direct measure of quenching sensitivity. A linear Stern-Volmer plot (Fig.2 inset) is generally indicative of single class of fluorophores and all equally accessible to the quencher.




**Figure 2:** Fluorescence quenching spectra of BSA (a) at pH 7.2 and in the presence of increasing concentration of PAS from 10  $\mu\text{M}$  (b), 20  $\mu\text{M}$  (c), 30  $\mu\text{M}$  (d), 40  $\mu\text{M}$  (e) and 50  $\mu\text{M}$  (f) respectively. The protein concentration was fixed at 10  $\mu\text{M}$  for all experiments.

### 3.3 Fourier Transformed Infrared Spectroscopy

To observe the effects of PAS on the BSA conformation, FT-IR measurements were performed and shown in Fig. 4. The FT-IR spectra of BSA at pH 7.2 shows an amide I band around 1600 ~ 1700  $\text{cm}^{-1}$  and amide II band around 1548  $\text{cm}^{-1}$ . Any change in these band range, indicates the change in protein secondary structure. [13] In Fig. 3, the amide I

band and amide II bands for free BSA were found at 1649  $\text{cm}^{-1}$  and 1545  $\text{cm}^{-1}$ , respectively. However, BSA on complexation with PAS, the amide I band shows almost no change but the amide II band shows a peak at 1546  $\text{cm}^{-1}$  and a new peak at 1523  $\text{cm}^{-1}$ . This may be due to the change in protein secondary structure after interaction with the drug PAS at physiological pH 7.2.




**Figure 3:** FT-IR spectra of BSA and BSA-PAS complexes.  $c(\text{BSA})=10 \mu\text{M}$  (a) and  $\text{BSA}-c(\text{PAS})=50 \mu\text{M}$  (b) at physiological pH 7.2.

### 3.4 Circular Dichroism

Circular dichroism (CD) is an important analytical method used to monitor the protein conformational changes. The near UV-CD spectra of fatty acid free BSA (Fig. 4) and its complexation with PAS were used to monitor the conformational changes of BSA and its interaction with PAS at physiological pH 7.2. The CD spectra of BSA shows two

negative bands at 208 nm ( $\pi \rightarrow \pi^*$  transition) and 222 nm ( $n \rightarrow \pi^*$  transition) respectively, which are characteristic of  $\alpha$ -helix protein. The binding of PAS to BSA shown an increase in negative molar ellipticity from 10  $\mu$ M to 50  $\mu$ M. This indicates the change in protein secondary structure upon PAS binding.



**Figure 4:** Near UV-CD spectra of BSA (a) and in the presence of different concentrations of PAS at pH 7.2.  $c(\text{BSA}) = 5 \mu\text{M}$  and  $c(\text{PAS}) = 10 \mu\text{M}$  to  $50 \mu\text{M}$ . For clarity, only  $10 \mu\text{M}$  (b) and  $50 \mu\text{M}$  (c) spectra have been shown.

### 4. Conclusions

The interaction of PAS with BSA have been investigated using spectroscopic methods. The UV absorbance and fluorescence quenching experiments results clearly indicate the significant interaction of the drug with BSA through the change in conformational stability. Further, the FT-IR and CD measurements confirms the interaction of the drug and conformational changes through the secondary structuration.

### 5. Acknowledgements

We are thankful to UGC, New Delhi, India for financial support through Major Research Project (MRP) to BCM [F.No.41/283/2012 (SR)].

### References

- [1] J. Zheng, E. J. Rubin, P. Bifani, V. Mathys, V. Lim, M. Au, J. Jang, J. Nam, T. Dick, J. R. Walke, K. Pethe, and L. R. Camacho, *J. Biol. Chem.* 2013, 288 (32), 23447–23456.
- [2] Nopponpunth, V., Sirawaraporn, W., Greene, P. J., and Santi, D. V. *J. Bacteriol.* 1999, 181, 6814–6821.
- [3] Rengarajan, J., Sassetti, C. M., Naroditskaya, V., Sloutsky, A., Bloom, B. R., and Rubin, E. J., *Mol. Microbiol.* 2004, 53, 275–282.
- [4] Ratledge, C., and Brown, K. A., *Am. Rev. Respir. Dis.* 1972, 106, 774–776.
- [5] Zhao XC, Liu RT., *Environ. Int.*, 2012, 40, 244–255.
- [6] Beauchemin R, N'Soukpoe-Kossi CN, Thomas TJ, Thomas T, Carpentier R, Tajmir-Riahi HA., *Biomacromolecules* 2007, 8, 3177–3183.
- [7] Brunaldi K, Huang N, Hamilton JA ., *J. Lipid Res.*, 2010, 51, 20-131.
- [8] Shim Y. Y., Reaney M. J. T., *J. Agric. Food Chem.* 2015, 63, 1099-1106.
- [9] Yamashita MM, Wesson L, Eisenman G, Eisenberg D., *Proc. Natl. Acad. Sci., USA* 1990, 87, 5648-5652.
- [10] Bal W, christo Doulou J, Sadler PJ, Tucker A., *J Inorg Biochem* 1998, 70, 33-39.
- [11] Zhou N, Liang Y-Z, Wang P., *J Phot. Photobio A Chem.* 2007, 185, 271-276.
- [12] Shang L, Jiang X, Dong S., *J Photochem Photobio A Chem* 2006, 184, 93-97.
- [13] Purcell M., Neault J.F., Malonga H., Arakawa H., Carpentier R., TajmirRiahi HA., *Biochim Biophys Acta* 2001, 1548, 129 – 138.